- Home
- SSL vs PRAX Comparison
SSL vs PRAX Comparison
Compare SSL & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSL
- PRAX
- Stock Information
- Founded
- SSL 1950
- PRAX 2015
- Country
- SSL South Africa
- PRAX United States
- Employees
- SSL N/A
- PRAX N/A
- Industry
- SSL Oil & Gas Production
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- SSL Energy
- PRAX Health Care
- Exchange
- SSL Nasdaq
- PRAX Nasdaq
- Market Cap
- SSL 4.0B
- PRAX 4.0B
- IPO Year
- SSL N/A
- PRAX 2020
- Fundamental
- Price
- SSL $6.54
- PRAX $187.33
- Analyst Decision
- SSL
- PRAX Strong Buy
- Analyst Count
- SSL 0
- PRAX 13
- Target Price
- SSL N/A
- PRAX $228.69
- AVG Volume (30 Days)
- SSL 1.2M
- PRAX 863.5K
- Earning Date
- SSL 01-01-0001
- PRAX 11-05-2025
- Dividend Yield
- SSL N/A
- PRAX N/A
- EPS Growth
- SSL N/A
- PRAX N/A
- EPS
- SSL 0.59
- PRAX N/A
- Revenue
- SSL $14,028,282,389.00
- PRAX $7,463,000.00
- Revenue This Year
- SSL $1.50
- PRAX N/A
- Revenue Next Year
- SSL $6.56
- PRAX $44.43
- P/E Ratio
- SSL $11.42
- PRAX N/A
- Revenue Growth
- SSL N/A
- PRAX 364.98
- 52 Week Low
- SSL $2.78
- PRAX $26.70
- 52 Week High
- SSL $7.39
- PRAX $206.71
- Technical
- Relative Strength Index (RSI)
- SSL 48.41
- PRAX 59.05
- Support Level
- SSL $6.82
- PRAX $160.11
- Resistance Level
- SSL $7.39
- PRAX $197.50
- Average True Range (ATR)
- SSL 0.21
- PRAX 16.19
- MACD
- SSL -0.02
- PRAX -4.53
- Stochastic Oscillator
- SSL 29.75
- PRAX 78.43
About SSL Sasol Ltd.
Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main businesses: the Southern Africa Energy & Chemicals business and the International Chemical business. It generates maximum revenue from the Southern Africa Energy & Chemicals business, which operates integrated value chains with feedstock sourced from the Mining and Gas operating segments. Geographically, the company generates the majority of its revenue from South Africa.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.